M&A
AstraZeneca Agrees to Buy US FDA Priority Review Voucher from Sobi
Nice Insight
PR-M08-19-NI-083-2192Aug 28, 2019
Clinical Trial
First Patient Dosed in Phase 1/2 Study Evaluating SOBI003 for Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)
Sobi
PR-M09-18-NI-012Sep 06, 2018